The IP disclosure process is online and simpler than ever — get started now in 5 easy steps.

Disclose an Invention

Innovation Life Cycle infographic.

Why disclose an invention?

Disclosure starts the Innovation Life Cycle, a process which allows our team of experts to assess the invention's commercial potential, provide feedback on market trends, and make a determination of Intellectual Property (IP) protection. This process provides the best opportunity to bring an invention to market and drive lasting societal and university-wide impact. Ideas disclosed to our office today can soon help fund future research in your department.

Who should disclose intellectual property?

UAB policies require all faculty members, university employees, and students to disclose any invention developed during employment or enrollment. Furthermore, federal and industry grants often require IP disclosure as a term of the award. If you believe you have created IP, contact our office before any public disclosure.

What can I disclose?

Inventions may include research tools, drugs and therapeutics, devices, curated patient samples, software, know-how, protocols or methods for teaching, trade secrets, art, music, literary works, etc. Anything with potential commercial or community value should be disclosed to our office.

What happens after disclosure?

  • A licensing associate is assigned to your IP case.
  • Feedback regarding the idea's patentability and market viability is returned within 30 days.
  • A patent protection decision is made collaboratively and the invention is marketed to potential licensees.
  • Once licensed, revenues are distributed to the inventor, department and school so the innovation continues!

Driving the Impact of UAB Research

See how UAB inventors are turning university IP into life-changing products and services.

Yuva Bioscences , LLC

Image of woman with illustration of DNA.

Project Summary

  • High-potential cosmeceutical startup based on UAB technology
  • Invention disclosed in 2018, licensed in 2019
  • Attracted executive leadership through HIIE network
  • Researcher to remain at UAB
  • Startup to operate in Birmingham

Details

Transforming dialysis with Continuous Renal Replacement Therapy (CRRT)

Image of woman with illustration of DNA.

Project Summary

  • Developed a patented citrate solution, Prismocitrate 18, which is safer than other citrate solutions available and helps patients who can’t tolerate regular dialysis and have to use CRRT instead, without having the issues of clotting.
  • Currently being used in multiple countries including Canada, India, Singapore, Australia, New Zealand, and is in process of obtaining FDA approval for use in the US.
  • Launched Tolwani Innovation Fund in Nephrology using licensing royalties

Details

AI Metrics

Image of woman with illustration of DNA.

Project Summary

  • Image viewing platform that leverages artificial intelligence and guided workflows
  • Assists radiologists with image analysis and reporting by automatically generating multimedia reports imaging biomarkers for cancer and other diseases
  • Initially developed the technology at University of Mississippi, launched startup from UAB in 2020
  • Received SBIR funding

TruSpin NanoMaterial Innovation

Image of woman with illustration of DNA.

Project Summary

  • 2019 UAB Anvil Student Startup Bootcamp program
  • Acquired license through HIIE to commercialize their production process
  • Creates solutions for the battery industry through innovations in Silicon-based nanofibers
  • Competed in the Alabama Launchpad pitch competition and awarded $50,000
  • Participating in 2020 Techstars Alabama EnergyTech Accelerator
  • Operate from Innovation Depot

Details

PEIR - Pathology Education Instructional Resource

Image of woman with illustration of DNA.

Project Summary

  • Developed PEIR database, the Pathology Education Instructional Resource
  • Serves as a web teaching and informatics training tool
  • hosts 34,000 images that can be used for medical education
  • Third parties including editors, authors, and documentarians request permission to use PEIR images for educational and informational purposes

Details

Pioneering Monoclonal Antibody Technology

Image of woman with illustration of DNA.

Project Summary

  • Research has enabled the easy generation of hybridoma cell lines for cloning and producing antibodies.
  • A by-product of the many antibodies developed as tools to support Kearney’s research program is a collection of hybridoma cell lines that produce antibodies in common use by research labs across the globe.
  • HIIE has licensed the hybridoma lines to multiple companies that produce, market, and sell antibodies worldwide.

Details

Our licensing experts are here to help

Karthik Gopalakrishnan

Ph.D.

Director of Licensing and New Ventures
This email address is being protected from spambots. You need JavaScript enabled to view it.
(205) 975-9443

Scott Swindle

Ph.D.

Licensing Associate
This email address is being protected from spambots. You need JavaScript enabled to view it.
(205) 996-7578

Sat Balachander

Ph.D.

Licensing Associate
This email address is being protected from spambots. You need JavaScript enabled to view it.
(205) 975-6851

Amanda Dove

Patent Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
(205) 996-4740